Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2026)
Rani Therapeutics Holdings' Gains from Investment Securities history spans 7 years, with the latest figure at $32000.0 for Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 4.99% to $32000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$4.7 million, a 14163.89% decrease, with the full-year FY2025 number at $12.9 million, up 25.84% from a year prior.
- Gains from Investment Securities came in at $32000.0 for Q1 2026, up from -$38000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $4.2 million in Q3 2024, with the low at -$4.7 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $416180.1 across 5 years, with a median of $83341.0 in 2023.
- Peak annual rise in Gains from Investment Securities hit 3223.55% in 2024, while the deepest fall reached 3020.37% in 2024.
- Year by year, Gains from Investment Securities stood at -$466000.0 in 2022, then soared by 134.76% to $162000.0 in 2023, then plummeted by 3020.37% to -$4.7 million in 2024, then surged by 99.2% to -$38000.0 in 2025, then soared by 184.21% to $32000.0 in 2026.
- Business Quant data shows Gains from Investment Securities for RANI at $32000.0 in Q1 2026, -$38000.0 in Q4 2025, and $1.6 million in Q3 2025.